News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Blueprint Medicines To Present On The First Isoform Selective FGFR4 Inhibitor At The American Association for Cancer Research Annual Meeting 2014


3/25/2014 9:12:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., March 24, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that new data on its first-in-class isoform selective fibroblast growth factor receptor 4 (FGFR4) inhibitor will be presented during a late-breaking minisymposium at the 105th Annual Meeting of the American Association for Cancer Research (AACR) taking place April 5-9, 2014, in San Diego, California. The presentation by Blueprint's Chief Scientific Officer Christoph Lengauer, Ph.D., will include preclinical data examining the impact of isoform selective FGFR4 inhibition in hepatocellular carcinoma with amplification or overexpression of FGF19 (fibroblast growth factor 19). FGF19 is the ligand of FGFR4 and a genomic driver in hepatocellular carcinoma.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES